The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 19 of the 79 sources its claims cite were checked for support.
Abstract
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 0 Not valid · 43 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“16S ribosomal RNA (rRNA)-based sequencing of gene amplicons and shotgun DNA sequencing of patient stool samples have identified subsets of bacteria more abundant in responding versus nonresponding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
The patient-stool analysis and Fig. 4 caption (page unavailable in our copy) identify bacterial clusters with differing Bacteroides abundance, and the paper reports 16S rRNA gene-amplicon sequencing of feces. But the treatment-response comparison was between mice receiving stool from different patient clusters, not responding versus nonresponding patients; our copy also does not report shotgun DNA sequencing of patient stool. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The indexed passage labeled Abstract (page not supplied) reports 16S rRNA sequencing of mouse fecal samples and identifies Bifidobacterium as associated with stronger antitumor responses. It does not report shotgun DNA sequencing or a comparison of responding and nonresponding patients; a later passage proposes sequencing patient stool as future work. (LLM, conf=0.88)
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The supplied passages (labelled Abstract; page not provided) describe 16S rRNA gene amplicon sequencing and metagenomic shotgun sequencing of patient stool samples. They report bacterial species differentially enriched in responders and nonresponders, including eight more abundant in responders. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Accordingly, B. fragilis and Burkholderia cepacia administered via gavage to mice reduced the severity of colitis induced by mAb to CTLA-4 (13,22).”
What the sources say
- Supportedcites [13] source
The passage labeled Abstract (discussion of Fig. 3A; page not provided) reports that reconstituting antibiotic-treated mice with a combination of B. fragilis and B. cepacia reduced histopathological signs of colitis induced by CTLA-4 blockade. The Fig. 3 caption describes oral gavage and assessment of colonic lesions in those mice. (LLM, conf=0.94)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
The Results section, “Members of Bacteroidetes phylum associated with resistance” (page unavailable), reports an association between Bacteroidetes abundance and resistance to colitis in melanoma patients. Our copy does not address whether gavage with B. fragilis and Burkholderia cepacia reduced colitis severity in mice; searches for both species and for mouse gavage found no such passage. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In patients with metastatic melanoma treated with the checkpoint inhibitor ipilimumab (antibody to CTLA-4), the abundance of Bacteroidetes inversely correlated with the severity of colitis (22).”
What the sources say
- Supportedcites [22] source
The Results section (‘Members of Bacteroidetes phylum associated with resistance’; page not provided) says the authors stratified patients by inflammation severity and found Bacteroidetes more abundant in colitis-free patients. The Methods identify the patients as adults with metastatic melanoma who received ipilimumab. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a study performed in 541 patients with hematologic malignancies reported that the gut microbiome at diagnosis influenced the probability of relapse within 2 years after ASCT.”
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The Methods and Results (page not provided) describe 541 patients with hematologic malignancies and assess microbiota associations with relapse or disease progression over two years. But the study concerns allogeneic HCT, not ASCT; its main cohort had stool samples collected within three weeks after transplantation, not at diagnosis. The Discussion describes an association, not evidence that the microbiome caused or influenced relapse. (LLM, conf=0.90)
plainstates an associationn = 541- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given these considerations, it is perhaps even more striking that bacteria generally associated with health (such as Clostridiales, Ruminococcacae, Faecalibacterium spp., Akkermansia muciniphila, B. fragilis,a n dBifidobacteria) (13, 14, 18-20) or immunogenicity (Enterococci, Collinsella, and Alistipes)( 11, 13, 14, 20) were found to be abundant in responding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
In the paper’s discussion of Fig. 4, stools from one patient microbiome cluster promoted colonization by immunogenic B. fragilis and B. thetaiotaomicron, and mice receiving those stools responded to CTLA-4 blockade. The passage does not establish that these bacteria were more abundant in patients who responded to treatment; the reported treatment responses were in recipient mice. It also does not support the sentence’s full list of bacteria. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The passage labeled Abstract reports that Enterococcus faecium and Collinsella aerofaciens were among eight species more abundant in responding patients. These support the immunogenic-bacteria portion of the cited sentence; the paper does not need to establish every organism listed alongside other citations. (LLM, conf=0.92)
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The paper’s indexed text (labeled Abstract; page unavailable) reports that Alistipes correlated positively with TNF production and that giving A. shahii to mice restored a tumor-associated immune response. This supports an immunogenic role for Alistipes, but the study does not show that it—or the other named bacteria—was abundant in responding patients. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
33 more claims · 2 with their cited sources checked
Create a free account to see all 67 claims and to verify the 60 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Particularly, immune checkpoint inhibitory (ICI) therapy and adoptive cell therapy using tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) can be influenced by the composition of the intestinal microbiota4,5.”
From Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, following the epidemiological demonstration of the negative effect of antibiotics on the efficacy of ICIs13,42,90, specific microbial taxa have been associated with response or resistance to ICIs across distinct cancer types26,38–40,42,91–100.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [30]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The gut microbiome and immuno-oncology
“immunotherapy through a combination of TLR9 antagonist and antibody to interleukin-10R (IL-10R) (11)”
§ The gut microbiome and immuno-oncology
“The immunizing effects of antibody to IL-10R + the TLR9 agonist CpG”
Citations
Cites
1 retracted
Lagier, J.-C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S. I., Seck, E. H., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.203 · Cited by 951
Self-citationRetractedGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Self-citationDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Cited by
Items 101–200 of 793
Xu, J., Ma, Q., Zhang, Y., Fei, Z., Sun, Y., Fan, Q., Liu, B., Bai, J., Yu, Y., Chu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27750-2 · Cited by 129
de la Iglesia, J. V., Slebos, R. J. C., Martin‐Gomez, L., Wang, X., Teer, J. K., Tan, A. C., Gerke, T. A., Aden-Buie, G., van Veen, T., Masannat, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1769 · Cited by 126
“, there is mounting data that the TIM-driven factors may be important in mounting the effective immune response (50).”
BackgroundGao, G., Shen, S., Zhang, T., Zhang, J., Huang, S. W., Sun, Z., & Zhang, H. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104533 · Cited by 124
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 113
Prognostic correlations with the microbiome of breast cancer subtypes
Banerjee, S., Wei, Z., Tian, T., Bose, D., Shih, N. N. C., Feldman, M. D., Khoury, T., De Michele, A., & Robertson, E. S. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04092-x · Cited by 117
“In addition, the cancer microbiome (oncobiome, inclusive of viruses, bacteria, fungi, and parasites) and its metabolites have a major impact on the local and distant immune system, which can influence clinical outcomes in cancer patients [11, 12].”
BackgroundKhan, M., Lin, J., Liao, G., Tian, Y., Liang, Y., Li, R., Liu, M., & Yuan, Y. (2018) · Medicine · doi:10.1097/md.0000000000011936 · Cited by 107
Sun, J., Chen, F., & Wu, G. (2023) · The ISME Journal · doi:10.1038/s41396-023-01483-0 · Cited by 126
Yonekura, S., Terrisse, S., Alves Costa Silva, C., Lafarge, A., Iebba, V., Ferrere, G., Goubet, A.-G., Fahrner, J.-E., Lahmar, I., Ueda, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0999 · Cited by 112
Self-citationThe gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
Gong, J., Chehrazi‐Raffle, A., Placencio‐Hickok, V., Guan, M., Hendifar, A., & Salgia, R. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0225-x · Cited by 113
“Additionally, greater understanding of underlying mechanisms may be afforded in research on the contribution of the microbiome to therapy-induced anticancer immune responses across other treatment modalities beyond checkpoint inhibition such as chemotherapy, radiation therapy, hematopoietic stem cell transplantation,…”
BackgroundMicrobial short-chain fatty acids: a strategy to tune adoptive T cell therapy
Rangan, P., & Mondino, A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004147 · Cited by 104
Customized materials-assisted microorganisms in tumor therapeutics
Chen, Q., Qiao, J., Liu, X., Zhang, C., & Zhang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01571g · Cited by 110
Gut microbiome and prostate cancer
Fujita, K., Matsushita, M., Banno, E., Velasco, M. A. D., Hatano, K., Nonomura, N., & Uemura, H. (2022) · International Journal of Urology · doi:10.1111/iju.14894 · Cited by 115
Tarallo, S., Ferrero, G., Gallo, G., Francavilla, A., Clerico, G. F., Luc, A. R., Manghi, P., Thomas, A. M., Vineis, P., Segata, N., et al. (2019) · mSystems · doi:10.1128/msystems.00289-19 · Cited by 111
“patient response to cancer chemotherapy and immunotherapy (56, 57).”
BackgroundDiet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
Szczyrek, M., Bitkowska, P., Chunowski, P., Czuchryta, P., Krawczyk, P. A., & Milanowski, J. (2021) · Nutrients · doi:10.3390/nu13072217 · Cited by 113
“However, there is a risk that bacteria might contribute to inflammation-induced carcinogenesis; therefore, this method has to be used cautiously [19,31,34,82,84,92].”
BackgroundMethodZheng, P., Li, Y., Wu, J., Zhang, H., Huang, Y., Tan, X., Pan, J., Duan, J., Liang, W., Yin, B., et al. (2019) · Advanced Science · doi:10.1002/advs.201901441 · Cited by 122
Hypoxia-Induced Resistance to Chemotherapy in Cancer
Minassian, L. M., Cotechini, T., Huitema, E., & Graham, C. H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_9 · Cited by 114
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Xie, J., Liu, M., Deng, X., Tang, Y., Zheng, S., Ou, X., Tang, H., Xie, X., Wu, M., & Zou, Y. (2024) · iMeta · doi:10.1002/imt2.156 · Cited by 108
“…samples collected from patients being treated with mAbs were analyzed using shotgun DNA sequencing, 16S rRNA sequencing, and metabolomics, and studies found that decreased diversity or richness of fecal bacterial composition was correlated with lower response rate and worse patient survival [42].”
MethodEffect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Lalani, A.-K. A., Xie, W., Braun, D. A., Kaymakcalan, M., Bossé, D., Steinharter, J. A., Martini, D. J., Simantov, R., Lin, X., Wei, X. X., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2019.09.001 · Cited by 100
“at the level of the colonic lamina propria, through potentiation of host antitumor immune responses [26,27].”
BackgroundHamada, T., Nowak, J. A., Milner, D. A., Song, M., & Ogino, S. (2019) · The Journal of Pathology · doi:10.1002/path.5236 · Cited by 105
Probiotics in microbiome ecological balance providing a therapeutic window against cancer
Sehrawat, N., Yadav, M. K., Singh, M. P., Kumar, V., Sharma, V., & Sharma, A. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.009 · Cited by 105
The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy
Assumpção, J. A. F., Pasquarelli-do-Nascimento, G., Viegas, M. S., Bonamino, M., & Magalhães, K. G. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00796-0 · Cited by 100
Crosstalk between gut microbiota and host immune system and its response to traumatic injury
Ullah, H., Arbab, S., Tian, Y., Chen, Y., Liu, C., Li, Q., & Li, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1413485 · Cited by 111
Oral delivery of bacteria: Basic principles and biomedical applications
Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 97
Inamura, K., Hamada, T., Bullman, S., Ugai, T., Yachida, S., & Ogino, S. (2022) · Gut · doi:10.1136/gutjnl-2022-327209 · Cited by 100
The Crosstalk between Microbiome and Immune Response in Gastric Cancer
Nasr, R., Shamseddine, A. I., Mukherji, D., Nassar, F. J., & Temraz, S. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186586 · Cited by 99
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 103
Precision cancer medicine: Concepts, current practice, and future developments
Edsjö, A., Holmquist, L., Geoerger, B., Nowak, F., Gomon, G., Alix‐Panabières, C., Staaf, J., Ploeger, C., Lassen, U., Tourneau, C. L., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13709 · Cited by 99
Burgos-Molina, A. M., Santana, T. T., Redondo, M., & Romero, M. J. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116188 · Cited by 100
“The intestinal microbiota also holds considerable sway over the CRC response to therapy, notably in the realm of immunotherapy [125].”
BackgroundBridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
Park, S.-Y., Rao, C., Coyte, K. Z., Kuziel, G. A., Zhang, Y., Huang, W., Franzosa, E. A., Weng, J., Huttenhower, C., & Rakoff-Nahoum, S. (2022) · Cell · doi:10.1016/j.cell.2022.01.002 · Cited by 92
Scoccianti, S., Olmetto, E., Pinzi, V., Osti, M. F., Franco, R. D., Caini, S., Anselmo, P., Matteucci, P., Franceschini, D., Mantovani, C., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab129 · Cited by 85
NIR light-responsive bacteria with live bio-glue coatings for precise colonization in the gut
Cui, M., Sun, T., Li, S., Pan, H., Liu, J., Zhang, X., Li, L., Li, S., Wei, C., Yu, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109690 · Cited by 81
A dysbiotic microbiome promotes head and neck squamous cell carcinoma
Frank, D. N., Qiu, Y., Cao, Y. Q., Zhang, S., Lu, L., Kofonow, J. M., Robertson, C. E., Liu, Y., Wang, H., Levens, C. L., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02137-1 · Cited by 86
Microbiota-driven antitumour immunity mediated by dendritic cell migration
Lin, Y.-T., Fukuoka, S., Koyama, S., Motooka, D., Tourlousse, D. M., Shigeno, Y., Matsumoto, Y., Yamano, H., Murotomi, K., Tamaki, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09249-8 · Cited by 90
“Our findings, together with previous reports 2,50–52 , suggest that gut microbiota diversity can serve as a pan-ethnic predictive biomarker for response to PD-1 blockade therapy across different cancer types.”
Terrisse, S., Goubet, A.-G., Ueda, K., Thomas, A. M., Quiniou, V., Thelemaque, C., Dunsmore, G., Clave, E., Gamat-Huber, M., Yonekura, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004191 · Cited by 80
“Indeed, recent work by multiple groups has revealed the cardinal importance of the gut microbiota in determining the general immune tonus, 34–36 as well as cross-reactive cancer antigen-specific immune responses.”
Self-citationRole of Lung Microbiome in Innate Immune Response Associated With Chronic Lung Diseases
Paudel, K. R., Dharwal, V., Patel, V. K., Galvão, I., Wadhwa, R., Malyla, V., Shen, S., Budden, K. F., Hansbro, N. G., Vaughan, A., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00554 · Cited by 84
“Furthermore, immunotherapy with monoclonal antibodies with immune checkpoint inhibitors like programmed cell death (PD)-1 and targeting its ligand PD-L1 is used in many metastatic cancers as a therapy (205).”
BackgroundVéziant, J., Villéger, R., Barnich, N., & Bonnet, M. (2021) · Cancers · doi:10.3390/cancers13092215 · Cited by 80
A dynamic atlas of immunocyte migration from the gut
Galván-Peña, S., Zhu, Y., Hanna, B. S., Mathis, D., & Benoist, C. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi0672 · Cited by 74
“Tumor-infiltrating MNPs are thought to be largely of monocyte origin, but our results, in agreement with a recent report ( 10 ) indicate a sizeable flow of MNPs from the gut, which may relay the documented effects of the gut microbiota on tumor sensitivity to checkpoint blockade ( 8 ).”
BackgroundResultInfluentialInfluence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy
Chen, Y., Liu, B., Wei, Y., & Kuang, D.-M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105966 · Cited by 73
Lu, L., Dong, J., Liu, Y., Qian, Y., Zhang, G., Zhou, W., Zhao, A., Ji, G., & Xu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964793 · Cited by 76
“Currently, the gut microbiota has attracted the attention of researchers in terms of its role in antitumor immunotherapy (Cremonesi et al., 2018; Zitvogel et al., 2018; Bouferraa et al., 2021; Matson et al., 2021; Xing et al., 2021).”
BackgroundMicrobiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy
Longhi, G., van Sinderen, D., Ventura, M., & Turroni, F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.575072 · Cited by 71
“Another means of intervention may be modulation of the autochthonous commensal microbial community via prebiotics or dietary changes to favor colonization and expansion of selected beneficial bacteria (Zitvogel et al., 2018).”
BackgroundAdvances in Salmonella Typhimurium-based drug delivery system for cancer therapy
Chen, W., Zhu, Y., Zhang, Z., & Sun, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114295 · Cited by 68
Mechanistic understanding of β-cryptoxanthin and lycopene in cancer prevention in animal models
Lim, J. Y., & Wang, X. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158652 · Cited by 76
Song, P., Chen, S. X., Yan, Y. H., Pinto, A., Cheng, L. Y., Dai, P., Patel, A. A., & Zhang, D. Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00713-0 · Cited by 76
Chen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67
Self-citationGao, H., Chi, X., Qin, W., Wang, L., Song, P., Cai, Z., Zhang, J., & Zhang, T. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14240 · Cited by 73
“…et al. 2018; Sun and Shen 2018), inflammatory bowel disease (IBD) (Costa et al. 2012; Roche-Lima et al. 2018), metabolic syndrome (Zhao et al. 2018), cancer and other diseases (Katsimichas et al. 2018; Lu et al. 2018; Panebianco et al. 2018; Pulikkan et al. 2018; Zitvogel et al. 2018).”
BackgroundThe interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era
Spyrou, N., Vallianou, N. G., Kadillari, J., & Dalamaga, Μ. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.008 · Cited by 72
A Reappraisal of Thymosin Alpha1 in Cancer Therapy
Costantini, C., Bellet, M. M., Pariano, M., Renga, G., Stincardini, C., Goldstein, A. L., Garaci, E., & Romani, L. R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00873 · Cited by 69
“the microorganisms that colonize the human body, can modulate the efficacy of checkpoint inhibitors, and perturbations of its composition, for instance following administration of antibiotics, may have a significant negative impact (104).”
BackgroundAutophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
Wang, Y., Xie, W., Humeau, J., Chen, G., Liu, P., Pol, J., Zhang, Z., Kepp, O., & Kroemer, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000462 · Cited by 63
“39 40 For this reason, it appears unlikely that the immune-dependent anticancer effects of thiostrepton would be related to its antibiotic activity.”
Self-citationZhu, R., Lang, T., Yan, W., Zhu, X. G., Huang, X. Y., Yin, Q., & Li, Y. (2021) · Advanced Science · doi:10.1002/advs.202003542 · Cited by 67
The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment
Luu, M., Schütz, B., Lauth, M., & Visekruna, A. (2023) · Cancers · doi:10.3390/cancers15051588 · Cited by 70
“efficient response to ICI treatment in humans and mice [29].”
BackgroundYang, M., Guo, J., Li, J., Wang, S., Sun, Y., Liu, Y., & Peng, Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03139-x · Cited by 76
A Bioinspired Versatile Spore Coat Nanomaterial for Oral Probiotics Delivery
Song, Q., Zhao, H., Zheng, C., Wang, K., Gao, H., Feng, Q., Zhang, H., Zhang, Z., Zhang, Y., & Wang, L. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202104994 · Cited by 66
Impact of bariatric surgery on cancer risk reduction
Bruno, D. S., & Berger, N. A. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.26 · Cited by 60
New tools to prevent cancer growth and spread: a ‘Clever’ approach
Hollmén, M., Figueiredo, C. R., & Jalkanen, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0953-0 · Cited by 76
Immunological classification of tumor types and advances in precision combination immunotherapy
Ren, X., Guo, S., Guan, X., Kang, Y., Liu, J., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790113 · Cited by 62
Wang, N., Wu, S., Huang, L., Hu, Y., He, X., He, J., Hu, B., Xu, Y., Rong, Y., Yuan, C., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01117-x · Cited by 62
“Intratumoral microbiomes may affect proximal and distant immunity and alter the clinical outcomes of patients with tumors [121, 122].”
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
Roles of microbiota in response to cancer immunotherapy
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.026 · Cited by 65
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.006 · Cited by 63
Kroemer, G., & Zitvogel, L. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201979 · Cited by 62
Self-citationImmunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03519-z · Cited by 91
“Whether it is caused by underlying disease or antibiotic administration, the dysbiosis of the gut microbiota may have a negative impact on the response to immunotherapy [104, 105].”
The intratumoral microbiome: Characterization methods and functional impact
Heymann, C. J. F., Bard, J.-M., Heymann, M.-F., Heymann, D., & Bobin-Dubigeon, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.009 · Cited by 57
Exploring the Gut Microbiome in Myasthenia Gravis
Thye, A. Y.-K., Law, J. W., Tan, L. T., Thurairajasingam, S., Chan, K., Letchumanan, V., & Lee, L. (2022) · Nutrients · doi:10.3390/nu14081647 · Cited by 69
“This further proves the function of the gut microbiome as the central regulator of the host immune homeostasis [59,85].”
BackgroundBacterial extracellular vesicle applications in cancer immunotherapy
Suri, K., D’souza, A. A., Huang, D., Bhavsar, A., & Amiji, M. M. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.10.024 · Cited by 73
The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome
Fujita, K., Matsushita, M., Velasco, M. A. D., Hatano, K., Minami, T., Nonomura, N., & Uemura, H. (2023) · Cancers · doi:10.3390/cancers15051375 · Cited by 67
The role of the gut microbiota in gastric cancer: the immunoregulation and immunotherapy
Wang, M., Yang, G., Tian, Y., Zhang, Q., Liu, Z., & Xin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183331 · Cited by 74
Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products
Kim, D.-Y., Lee, S.-Y., Lee, J., Whon, T. W., Lee, J., Jeon, C. O., & Bae, J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2412376 · Cited by 67
Liu, P., Jiang, Y., Gu, S., Xue, Y., Yang, H., Li, Y., Wang, Y., Yan, C., Jia, P., Lin, X., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02034-0 · Cited by 68
Male‐Biased Gut Microbiome and Metabolites Aggravate Colorectal Cancer Development
Wang, L., Tu, Y., Chen, L., Zhang, Y., Pan, X., Yang, S., Zhang, S., Li, S., Yu, K., Song, S., et al. (2023) · Advanced Science · doi:10.1002/advs.202206238 · Cited by 67
Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?
Smith, L. K., Arabi, S., Lelliott, E. J., McArthur, G. A., & Sheppard, K. E. (2020) · Cancers · doi:10.3390/cancers12061583 · Cited by 64
“Furthermore, obesity also impacts on gut microbiome diversity [127] which can play a role in response to immune checkpoint blockade efficacy in cancer including melanoma [128,129].”
BackgroundAn Update on the Effects of Probiotics on Gastrointestinal Cancers
Davoodvandi, A., Fallahi, F., Tamtaji, O. R., Tajiknia, V., Banikazemi, Z., Fathizadeh, H., Abbasi‐Kolli, M., Aschner, M., Ghandali, M., Sahebkar, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.680400 · Cited by 61
“Populating the gut microbiota in cancer patients with probiotics re-establishes both the functionality and quantities of commensal bacteria, which are reduced after treatments (Zitvogel et al., 2018).”
BackgroundIntratumoral microbiota: A new force in diagnosing and treating pancreatic cancer
Jiang, Z., Zhang, W., Zhang, Z., Sha, G., Wang, D., & Tang, D. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216031 · Cited by 62
The Gut Microbiome in Autism: Study-Site Effects and Longitudinal Analysis of Behavior Change
Fouquier, J., Huizar, N. M., Donnelly, J., Glickman, C. M., Kang, D., Maldonado, J., Jones, R. A., Johnson, K. A., Adams, J. B., Krajmalnik‐Brown, R., et al. (2021) · mSystems · doi:10.1128/msystems.00848-20 · Cited by 64
“Indeed, greater volatility of the gut microbiome over time has been linked with disease in other systems, such as increased risk of infection in cancer patients and inflammatory bowel disease (49).”
BackgroundThe role of the bacterial microbiome in the treatment of cancer
Yu, Z., Xie, R., You, R., Liu, Y., Chen, X.-Y., Chen, M., & Huang, P.-Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08664-0 · Cited by 62
Butyrate Properties in Immune-Related Diseases: Friend or Foe?
Anshory, M., Effendi, R. M. R. A., Kalim, H., Dwiyana, R. F., Suwarsa, O., Nijsten, T. E. C., Nouwen, J. L., & Thio, H. B. (2023) · Fermentation · doi:10.3390/fermentation9030205 · Cited by 62
Long-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 58
Self-citationMultifaceted modes of action of the anticancer probiotic Enterococcus hirae
Goubet, A.-G., Wheeler, R., Fluckiger, A., Qu, B., Lemaître, F., Iribarren, K., Mondragón, L., Tidjani Alou, M., Pizzato, E., Durand, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00753-8 · Cited by 54
“and treatment, to boost therapeutic effects or alleviate side effects [19].”
BackgroundSelf-citationThe critical role of tumor microbiome in cancer immunotherapy
Yang, L., Wang, Q., He, L., & Sun, X. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2301801 · Cited by 55
Human gut, breast, and oral microbiome in breast cancer: A systematic review and meta-analysis
Thu, M. S., Chotirosniramit, K., Nopsopon, T., Hirankarn, N., & Pongpirul, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144021 · Cited by 60
“Identifying the microbiome of the four BC subtypes may reveal a link between the microbiota and the therapeutic response (71, 72).”
BackgroundA new era in healthcare: The integration of artificial intelligence and microbial
Huo, D.-L., & Wang, X. (2024) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2024.100319 · Cited by 51
Devaux, C. A., & Raoult, D. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01379 · Cited by 54
“Moreover, it was recently shown that efficacy of cancer immunotherapy with immune checkpoint antibodies requires specific gut microbiota and is decreased by antibiotic treatments (Zitvogel et al., 2018).”
Self-citationThe Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tunger, A., Sommer, U. J., Wehner, R., Kubasch, A. S., Grimm, M., Bachmann, M. P., Platzbecker, U., Bornhäuser, M., Baretton, G. B., & Schmitz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101534 · Cited by 55
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
Puccini, A., Battaglin, F., Iaia, M. L., Lenz, H., & Salem, M. E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000404 · Cited by 55
“107 108 Other tumor-extrinsic mechanisms include changes in immune checkpoint expression (eg, CTLA-4 and PD-1), T-cell exhaustion and phenotype change, recruitment of immune suppressive cell populations (eg, T-regs, MDSC and type II macrophages), and cytokine or metabolite release in the tumor…”
BackgroundCurrent Trends and Challenges of Fecal Microbiota Transplantation—An Easy Method That Works for All?
Almeida, C., Oliveira, R., Baylina, P., Fernandes, R., Teixeira, F. G., & Barata, P. (2022) · Biomedicines · doi:10.3390/biomedicines10112742 · Cited by 56
Metabolites as agents and targets for cancer immunotherapy
Trefny, M. P., Kroemer, G., Zitvogel, L., & Kobold, S. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01227-z · Cited by 66
Self-citationZheng, P., Li, Y., Wu, J., Zhang, H., Huang, Y., Tan, X., Pan, J., Duan, J., Liang, W., Yin, B., et al. (2020) · Advanced Science · doi:10.1002/advs.202001296 · Cited by 54
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer
Zhang, C., Yang, M. J., & Ericsson, A. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.524205 · Cited by 52
Devaux, C. A., Million, M., & Raoult, D. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01642 · Cited by 53
“…checkpoint inhibitors (such as CTLA-4 or PD1/PD-L1 inhibitor antibodies) in the treatment of cancers has changed the outcome of several of such severe diseases and highlighted the strong molecular crosstalk between the microbiota and the immune system (Zitvogel et al., 2018; Gong et al., 2019).”
BackgroundSelf-citationSingh, N., Beckett, J. M., Kalpurath, K., Ishaq, M., Ahmad, T., & Eri, R. D. (2023) · Nutrients · doi:10.3390/nu15071759 · Cited by 52
“The administration of probiotics in cancer patients re-establishes the abundance and the functionality of the commensal gut bacteria, which has been affected by anticancer treatment [115].”
BackgroundWadan, A.-H. S., El‐Aziz, M. K. A., & Ellakwa, D. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04155-2 · Cited by 60
“Microbiota-responsive drug delivery systems are specifically engineered to release therapeutic compounds in reaction to particular alterations in the GM (Zitvogel et al. 2018a).”
Confirming putative variants at ≤ 5% allele frequency using allele enrichment and Sanger sequencing
Yan, Y. H., Chen, S. X., Cheng, L. Y., Rodriguez, A. Y., Tang, R., Cabrera, K., & Zhang, D. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-91142-1 · Cited by 63
Roccuzzo, G., Moirano, G., Fava, P., Maule, M. M., Ribero, S., & Quaglino, P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.010 · Cited by 51
Hydrogels as promising platforms for engineered living bacteria-mediated therapeutic systems
Yu, S., Sun, H., Li, Y., Wei, S., Xu, J., & Liu, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100435 · Cited by 60
Zhu, Z., Ren, J., Michail, S. K., & Sun, F. (2019) · Genome biology · doi:10.1186/s13059-019-1773-5 · Cited by 49
“In addition, human microbiota has been linked to the effectiveness of cancer chemotherapy [12].”
BackgroundWang, L., Mo, Y. Y., Huang, Y., Echeveste, C. E., Wang, H., Chen, J., Oshima, K., Yearsley, M., Simal‐Gandaraf, J., Battino, M., et al. (2020) · eFood · doi:10.2991/efood.k.200824.002 · Cited by 45
“In addition to using animal models to investigate the effects of foods on gut microbiota that has been summarized elsewhere [10-12], the approach of in vitro gastrointestinal digestion of food components was also widely used [13,14].”
BackgroundGinsenoside Rk3 Suppresses Hepatocellular Carcinoma Development through Targeting the Gut-Liver Axis
Qu, L., Ma, X., & Fan, D. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c03279 · Cited by 48
Alterations of the human skin microbiome after ocean water exposure
Nielsen, M. C., & Jiang, S. C. (2019) · Marine Pollution Bulletin · doi:10.1016/j.marpolbul.2019.06.047 · Cited by 50
“The microbiome is currently believed to be an integral part of our immune system because of the association between host and microbial factors and the downstream effects on immune cells (Belkaid and Tamoutounour, 2016; Zitvogel et al., 2018).”
Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
Indini, A., Rijavec, E., Ghidini, M., Tomasello, G., Cattaneo, M., Barbin, F., Bareggi, C., Galassi, B., Gambini, D., & Grossi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052628 · Cited by 50
“Furthermore, gender and obesity also impact on the composition of gut microbiome with well-known implications on ICIs efficacy [42].”
Metadata
- Authors
- Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F.
- Affiliations
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Centre National de la Recherche Scientifique (FR)
- Sorbonne Paris Cité (FR)
- University of Chicago (US)
- Corresponding author
- Zitvogel, Laurence
- Gajewski, Thomas F.
- Venue
- Science
- Published
- 2018-03-23
- Volume
- 359
- Issue
- 6382
- Pages
- 1366-1370
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2791926234
- Cited by
- 777
- References
- 74
- Citations by year
- 2026: 84 · 2025: 85 · 2024: 74 · 2023: 96 · 2022: 84 · 2021: 130 · 2020: 105 · 2019: 81 · 2018: 37
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Melanoma Research Alliance (CA210098)
- University of Chicago (T32 CA009594)
- Association pour la Recherche sur le Cancer
- Seerave Foundation
- Jounce Therapeutics
- Incyte
- E-Rare
- European Commission
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Fondation Leducq
- National Natural Science Foundation of China (81671630, CAMS-I2M, 2017YFA0506200, 81722037)
- Fondation pour la Recherche Médicale
- Government of Jiangsu Province
- Ligue Contre le Cancer
- Natural Science Foundation of Jiangsu Province (BK20170006, BK20160379)
- Institut Universitaire de France
- Chinese Academy of Medical Sciences (2016‐I2M‐1‐005, (CAMS-I2M), 2017RC31008, 2017NL31004, 2016ZX310194)
- Institut National Du Cancer
- Institut Gustave-Roussy
- Recruitment Program of Global Experts
- Genentech
- University of Chicago Medicine
- National Key Research and Development Program of China (2017YFA0506200)
- Labex Immuno-Oncology
- Comprehensive Cancer Center, University of Chicago Medical Center (T32 CA009594)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, host-microbe interactions, precision medicine, microbiome-based diagnostics, microbiota-based therapy, cancer immunotherapy resistance
- MeSH terms
- Gastrointestinal Microbiome, Humans, Immune System, Immunotherapy, Neoplasms, Treatment Outcome, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.